Advances in the management of endometriosis: An update for clinicians

Human Reproduction Update

Volumn 12, Issue 2, 2006, Pages 179-189

  Crosignani, PierGiorgio ^a   Olive, David ^b   Bergqvist, Agneta ^c   Luciano, Anthony ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Androgens; Endometriosis; GnRH (AG ANTAG); Progesterone; Surgery

Indexed keywords

ALENDRONIC ACID; AROMATASE; AROMATASE INHIBITOR; BUSERELIN; CALCIUM; CONJUGATED ESTROGEN; DANAZOL; DYDROGESTERONE; ESTRADIOL; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; GESTAGEN; GESTRINONE; GONADORELIN DERIVATIVE; GONADOTROPIN; GOSERELIN; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NAFARELIN; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIPTORELIN; UNINDEXED DRUG;

ACNE; AMENORRHEA; ANALGESIA; BLEEDING DISORDER; BLOATING; BODY WEIGHT DISORDER; BREAST ATROPHY; BREAST TENSION; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSMENORRHEA; DYSPAREUNIA; EDEMA; ENDOMETRIOSIS; FEMALE INFERTILITY; FLUID RETENTION; HEADACHE; HIRSUTISM; HOT FLUSH; HUMAN; LIBIDO DISORDER; MEDICAL PRACTICE; MENOPAUSE; MENTAL INSTABILITY; METABOLIC DISORDER; MYALGIA; OILY SKIN; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURGICAL TECHNIQUE; TREATMENT INDICATION; VAGINAL DRYNESS;

AROMATASE INHIBITORS; CONTRACEPTIVES, ORAL, COMBINED; DANAZOL; ENDOMETRIOSIS; ESTROGEN RECEPTOR MODULATORS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONES; HUMANS; PROGESTINS; QUALITY OF LIFE; RECEPTORS, PROGESTERONE;

EID: 32444451851     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/dmi049     Document Type: Review

References (94)

1. Abbott J, Hawe J, Hunter D, Holmes M, Finn P and Garry R (2004) Laparoscopic excision of endometriosis: A randomized, placebo-controlled trial. Fertil Steril 82,878-884.
2. Abrams LS, Skee D, Natarajan J and Wong FA (2002) Pharmacokinetic overview of Ortho Evra™/Evra™. Fertil Steril 77,S3-S12.
3. Ailawadi RK, Jobanputra S, Kataria M, Gurates B and Bulun SE (2004) Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: A pilot study. Fertil Steril 81,290-296.
4. Archer DF, Cullins V, Creasy GW and Fisher AC (2004) The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra®) on contraceptive efficacy. Contraception 69,189-195.
5. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, Creasy GW for the ORTHO EVRA/EVRA 004 Study Group (2001) Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: A randomized controlled trial. JAMA 285,2347-2354.
6. Barnhart K, Dunsmoor-Su R and Coutifaris C (2002) Effect of endometriosis on in vitro fertilization. Fertil Steril 77,1148-1155.
7. Berenson AB, Radecki CM, Grady JJ, Rickert VI and Thomas A (2001) A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 98,576-582.
8. Bergqvist A and Theorell T (2001) Changes in quality of life after hormonal treatment of endometriosis. Acta Obstet Gynecol Scand 80,628-637.
9. Bérubé S, Marcoux S, Maheux R and the Canadian Collaborative Group on Endometriosis (1998) Characteristics related to the prevalence of minimal or mild endometriosis in infertile women. Epidemiology 9,504-510.
10. Biberoglu KO and Behrman SJ (1981) Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness. Am J Obstet Gynecol 139,645-654.
11. Blei F, Wilson EL, Mignatti P and Rifkin DB (1993) Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 155,568-578.
12. Bulun SE, Zeitoun K, Takayama K, Noble L, Michael D, Simpson E, Johns A, Putman M and Sasano H (1999) Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer 6,293-301.
13. Bulun SE, Fang Z, Imir G, Gurates B, Tamura M, Yilmaz B, Langoi D, Amin S, Yang S and Deb S (2004) Aromatase and endometriosis. Semin Reprod Med 22,45-50.
14. Chang SP and Ng HT (1996) A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chin Med J (Taipei) 57,431-437.
15. Cheewadhanaraks S, Peeyananjarassri K, Dhanaworavibul K and Liabsuetrakul T (2004) Positive predictive value of clinical diagnosis of endometriosis. J Med Assoc Thai 87,740-744.
16. Child TJ and Tan SL (2001) Endometriosis: Aetiology, pathogenesis and treatment. Drugs 61,1735-1750.
17. Chwalisz K, Garg R, Brenner RM, Schubert G and Elger W (2002) Selective progesterone receptor modulators (SPRMs): A novel therapeutic concept in endometriosis. Ann N Y Acad Sci 955,373-388 [discussion 389-393, 396-406].
18. Cirkel U, Ochs H and Schneider HPG (1995) A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. Eur J Obstet Gynecol Reprod Biol 59,61-69.
19. Cosson M, Querleu D, Donnez J, Madelenat P, Koninckx P, Audebert A and Manhes H (2002) Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: Results of a prospective, multicenter, randomized study. Fertil Steril 77,684-692.
20. Crosignani PG, Gastaldi A, Lombardi PL, Montemagno U, Vignali M, Serra GB and Stella C (1992) Leuprorelin acetate depot vs danazol in the treatment of endometriosis: Results of an open multicentre trial. Clin Ther 14,29-36.
21. Crosignani PG, Luciano A, Ray A and Bergqvist A (2005) Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. Epub ahead of print September 21, 2005.
22. Cundy T, Cornish J, Roberts H, Elder H and Reid IR (1998) Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 92,569-573.
23. D'Hooghe TM, Debrock S, Hill JA and Meuleman C (2003) Endometriosis and subfertility: Is the relationship resolved? Semin Reprod Med 21,243-253.
24. Donnez J, Dewart PJ, Hedon B, Perino A, Schindler AE, Blumberg J and Querleu D (2004) Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis. Fertil Steril 81,297-304.
25. ESHRE Capri Workshop Group (2001) Ovarian and endometrial function during hormonal contraception. Hum Reprod 16,1527-1535.
26. Eskenazi B and Warner ML (1997) Epidemiology of endometriosis. Obstet Gynecol Clin North Am 24,235-258.
27. Filicori M, Flamigni C, Cognigni G, Dellai P, Arnone R, Falbo A and Capelli M (1993) Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J Clin Endocrinol Metab 77,130-133.
28. Fraser IS, Shearman RP, Jansen RPS and Sutherland PD (1991) A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Aust N Z J Obstet Gynaecol 31,158-163.
29. Gazvani R and Templeton A (2002) Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 123,217-226.
30. Gbolade B, Ellis S, Murby B, Randall S and Kirkman R (1998) Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 105,790-794.
31. Gestrinone Italian Study Group (1996) Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertil Steril 66,911-919.
32. Gianetto-Berrutti A and Feyles V (2003) Endometriosis related to infertility. Minerva Ginecol 55,407-416.
33. Gurates B and Bulun SE (2003) Endometriosis: The ultimate hormonal disease. Semin Reprod Med 21,125-134.
34. Haney AF and Weinberg JB (1988) Reduction of the intraperitoneal inflammation associated with endometriosis by treatment with medroxyprogesterone acetate. Am J Obstet Gynecol 159,450-454.
35. Henzl MR and Loomba PK (2003) Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. J Reprod Med 48,525-540.
36. Hornstein MD, Hemmings R, Yuzpe AA and Heinrichs WL (1997) Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 68,860-864.
37. Hornstein MD, Surrey ES, Weisberg GW, Casino LA for the Lupron Add-Back Study Group (1998) Leuprolide acetate depot and hormonal add-back in endometriosis: A 12-month study. Obstet Gynecol 91,16-24.
38. Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode FR and Mishell DR Jr (2004a) Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera®. Contraception 70,11-18.
39. Jain J, Jakimiuk AJ, Bode FR, Ross D and Kaunitz AM (2004b) Contraceptive efficacy and safety of DMPA-SC. Contraception 70,269-275.
40. Jones GL, Kennedy SH and Jenkinson C (2002) Health-related quality of life measurement in women with common benign gynecologic conditions: A systematic review. Am J Obstet Gynecol 187,501-511.
41. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A and Saridogan E (2005) ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 20,2698-2704.
42. Lockhat FB, Emembolu JO and Konje JC (2004) The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum Reprod 19,179-184.
43. Luciano AA, Turksoy RN and Carleo J (1988) Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol 72,323-327.
44. Lupron Depot [package insert] (2004) Tap Pharmaceuticals, Lake Forest, IL.
45. Marques A, Bahamondes L, Aldrighi JM and Petta CA (2004) Quality of life in Brazilian women with endometriosis assessed through a medical outcome questionnaire. J Reprod Med 49,115-120.
46. Meresman GF, Augé L, Barañao RI, Lombardi E, Tesone M and Sueldo C (2002) Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis. Fertil Steril 77,1141-1147.
47. Milingos S, Protopapas A, Drakakis P, Liapi A, Loutradis D, Kallipolitis G, Milingos D and Michalas S (2003) Laparoscopic management of patients with endometriosis and chronic pelvic pain. Ann N Y Acad Sci 997,269-273.
48. Miller JD (2000) Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: A double-blind, randomized, placebo-controlled trial. Am J Obstet Gynecol 182,1483-1488.
49. Muzii L, Marana R, Caruana P, Catalano GF, Margutti F and Panici PB (2000) Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: A prospective, randomized trial. Am J Obstet Gynecol 183,588-592.
50. Nelson A (2002) Merits of DMPA relative to other reversible contraceptive methods. J Reprod Med 47,781-784.
51. Novák A, de la Loge C, Abetz L and van der Meulen EA (2003) The combined contraceptive vaginal ring, NuvaRing®: An international study of user acceptability. Contraception 67,187-194.
52. NuvaRing [prescribing information] (2003). Organon, West Orange, NJ.
53. Olive DL (2002) Role of progesterone antagonists and new selective progesterone receptor modulators in reproductive health. Obstet Gynecol Surv 57,S55-S63.
54. Olive DL and Henderson DY (1987) Endometriosis and mullerian anomalies. Obstet Gynecol 69,412-415.
55. On-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T and Reid IR (1998) The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 49,615-618.
56. Overton CE, Lindsay PC, Johal B, Collins SA, Siddle NC, Shaw RW and Barlow DH (1994) A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Fertil Steril 62,701-707.
57. Paiva LC, Pinto-Neto AM and Faundes A (1998) Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception 58,351-355.
58. Parazzini F, Di Cintio E, Chatenoud L, Moroni S, Ardovino I, Struzziero E, Falsetti L, Bianchi A, Bracco G, Pellegrini A et al. (2000) Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: A randomized trial. Gruppo Italiano per to Studio dell'Endometriosi. Eur J Obstet Gynecol Reprod Biol 88,11-14.
59. Perotti M, Bahamondes L, Petta C and Castro S (2001) Forearm bone density in long-term users of oral combined contraceptives and depot medroxy-progesterone acetate. Fertil Steril 76,469-473.
60. Regidor PA, Regidor M, Schmidt M, Ruwe B, Lübben G, Förtig P, Kienle E and Schindler AE (2001) Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol 15,202-209.
61. Rice VM (2002) Conventional medical therapies for endometriosis. Ann N Y Acad Sci 955,343-352.
62. Riggs BL and Hartmann LC (2003) Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 348,618-629.
63. Rosenberg M and Waugh MS (1999) Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 180,S276-S279.
64. Rosenberg MJ, Waugh MS and Meehan TE (1995) Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation. Contraception 51,283-288.
65. Rotondi M, Labriola D, Rotondi M, Ammaturo FP, Amato G, Carella C, Izzo A and Panariello S (2002) Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. Eur J Gynaecol Oncol 23,523-526.
66. Roumen FJ, Apter D, Mulders TM and Dieben TO (2001) Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 16,469-475.
67. Saito T, Yoshizawa M, Yamauchi Y, Kinoshita S, Fujii T, Mieda M, Sone H, Yamamoto Y and Koizumi N (2003) Effects of the novel orally active antiestrogen TZE-5323 on experimental endometriosis. Arzneimittelforschung/Drug Res 53,507-514.
68. Schlaff WD, Carson SA, Luciano A, Ross D and Bergqvist A (in press) Subcutaneous injection of depot medroxyprogesterone acetate (DMPA-SC 104) compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril.
69. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE and Ott SM (2002) Injectable hormone contraception and bone density: Results from a prospective study. Epidemiology 13,581-587.
70. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE and Ott SM (2004) The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception 69,99-104.
71. Schweppe K-W (2001) Current place of progestins in the treatment of endometriosis-related complaints. Gynecol Endocrinol 15,22-28.
72. Seli E, Berkkanoglu M and Arici A (2003) Pathogenesis of endometriosis. Obstet Gynecol Clin North Am 30,41-61.
73. Shaw RW (2003) Evaluation of the role of laser treatment for the treatment of pain in endometriosis. Ann N Y Acad Sci 997,240-246.
74. Takayama K, Zeitoun K, Gunby RT, Sasano H, Carr BR and Bulun SE (1998) Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 69,709-713.
75. Tang OS, Tang G, Yip PS and Li B (2000) Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: A longitudinal cohort study. Contraception 62,161-164.
76. Telimaa S, Puolakka J, Rönnberg L and Kauppila A (1987a) Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1,13-23.
77. Telimaa S, Rönnberg L and Kauppila A (1987b) Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecol Endocrinol 1,363-371.
78. The Australian/New Zealand ZOLADEX Study Group (1996) Goserelin depot versus danazol in the treatment of endometriosis. The Australian/New Zealand experience. Aust N Z J Obstet Gynaecol 36,55-60.
79. Timmer CJ and Mulders TM (2000) Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 39,233-242.
80. Valle RF and Sciarra JJ (2003) Endometriosis: Treatment strategies. Ann N Y Acad Sci 997,229-239.
81. Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M and Crosignani PG (1993) A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 60,75-79.
82. Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S and Crosignani PG (1996) Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 175,396-401.
83. Vercellini P, Cortesi I and Crosignani PG (1997) Progestins for symptomatic endometriosis: A critical analysis of the evidence. Fertil Steril 68,393-401.
84. Vercellini P, De Giorgi O, Pisacreta A, Pesole AP, Vicentini S and Crosignani PG (2000) Surgical management of endometriosis. Baillieres Best Pract Res Clin Obstet Gynaecol 14,501-523.
85. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E and Crosignani PG (2003a) Progestogens for endometriosis: Forward to the past. Hum Reprod Update 9,387-396.
86. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R and Crosignani PG (2003b) Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorhea that does not respond to a cyclic pill regimen. Fertil Steril 80,560-563.
87. Viganò P, Mangioni S, Odorizzi MP, Chiodini A, Rocca S and Chiodo I (2003) Use of estrogen antagonists and aromatase inhibitors in endometriosis. Curr Opin Investig Drugs 4,1209-1212.
88. Waller KG and Shaw RW (1993) Gonadotropin-releasing hormone analogues for the treatment of endometriosis: Long-term follow-up. Fertil Steril 59,511-515.
89. Wenzl R, Kiesel L, Huber JC and Wieser F (2003) Endometriosis: A genetic disease. Drugs Today (Barc) 39,961-972.
90. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1997) Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study. Lancet 349,1202-1209.
91. Winkel CA (2000) A cost-effective approach to the management of endometriosis. Curr Opin Obstet Gynecol 12,317-320.
92. Winkel CA (2003) Evaluation and management of women with endometriosis. Obstet Gynecol 102,397-408.
93. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC and Creasy GW (2002) Contraceptive efficacy and cycle control with the Ortho Evra™/ Evra™ transdermal system: The analysis of pooled data. Fertil Steril 77,S13-S18.
94. Zupi E, Marconi D, Sbracia M, Zullo F, De Vivo B, Exacustos C and Sorrenti G (2004) Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril 82,1303-1308.